GMP News and Research

RSS

First batch of cancer vaccine from Cancer Vaccine Collaborative goes into trial

The first batch of NY-ESO-1 recombinant protein produced in a facility supported entirely by non-profit entities has successfully cleared regulatory review and has entered clinical testing. The clinical trials are part of the Cancer Vaccine Collaborative, a joint program of the Cancer Research Institute, Inc. (CRI) and the Ludwig Institute for Cancer Research Ltd. (LICR).

13 Aug 2009

Research reveals new options for people with phenylketonuria

For people with the genetic condition known as phenylketonuria (PKU), diet is a constant struggle.

30 Mar 2009

Protecting the public from food-borne illness and food associated hazards are main goal as addressed by food scientist

At the Institute of Medicine (IOM) and National Research Council (NRC) meeting held on March 24, Institute of Food Technologists (IFT) food scientist Dr. Frank Busta addressed food safety gaps in the Food Protection Plan by the U.S. Food and Drug Administration (FDA).

30 Mar 2009

Nationwide alert on tainted weight loss products

The U.S. Food and Drug Administration is expanding, for the second time, its nationwide alert to consumers about tainted weight loss products containing

22 Mar 2009

Gene therapy used to fight AIDS

The apparent success of a case in which German doctors cured a man of AIDS using a bone marrow transplant comes as no surprise to Gerhard Bauer, a UC Davis stem cell researcher.

8 Dec 2008

Scientists map steps to block enzyme phosphodiesterase 5's action in heart failure

Taking a cue from the way drugs like Viagra put the biological brakes on a key enzyme involved in heart failure, scientists at Johns Hopkins have mapped out a key chemical step involved in blocking the enzyme.

12 Nov 2008

Anadis to commercialise "BioGard" adjunctive therapy for HIV/AIDS

Anadis announced today its commercialization of a new product, BioGard, intended to maintain gastrointestinal and immune system health. The specific formulation may be of particular clinical benefit in persons undergoing antiretroviral therapy for HIV/AIDS.

4 Sep 2008

A glimpse of ancient RNA

Some bacterial cells can swim, morph into new forms and even become dangerously virulent - all without initial involvement of DNA. Yale University researchers describe Friday in the journal Science how bacteria accomplish this amazing feat - and in doing so provide a glimpse of what the earliest forms of life on Earth may have looked like.

19 Jul 2008

EpiCept and GNI partner to develop anti-viral hepatitis drug in Asia

GNI Ltd and EpiCept Corporation have announced that they have reached agreement to develop a new therapeutic drug, EP1013, in Asia, Australia, and New Zealand, for late-stage viral infection-induced hepatitis. EpiCept will retain the rights in the rest of the world. GNI’s wholly owned subsidiary, Shanghai Genomics, will start preparation for pre-IND and clinical development in China immediately.

17 Jul 2008

Japan awards new prize for HIV/AIDS, malaria work in Africa

Japan recently awarded the first Hideo Noguchi Prize to two recipients for their work on HIV/AIDS and malaria in Africa, AFP/Google.com reports.

30 May 2008

Adult human stem cells shown not to pose a cancer risk when implanted into different organs

A new study by UC Davis researchers provides evidence that methods using human bone marrow-derived stem cells to deliver gene therapy to cure diseases of the blood, bone marrow and certain types of cancer do not cause the development of tumors or leukemia.

6 May 2008

Biosimilar protein cooperation

A biosimilar protein that can be used to treat neutropenia (a side effect of cancer chemotherapy) is to be developed by Apotex Inc. of Canada in collaboration with Intas Biopharmaceuticals Limited (IBPL).

6 May 2008

LifeSync to sublicense patent portfolio to Triage Wireless

LifeSync Corporation, a wholly owned subsidiary of GMP Companies, Inc., announced it has entered into a non-exclusive sublicense with Triage Wireless Inc. for LifeSync's patent portfolio associated with the digital, wireless communication of patient vital signs.

23 Apr 2008

Aida Pharmaceuticals announces development of new anti-cancer drug

Aida Pharmaceuticals, Inc. has announced that it is developing a potential cancer drug that seeks to trigger cell death in certain types of cancer.

18 Apr 2008

Effective treatment of smell loss with theophylline

Despite the fact that millions of Americans are believed to have lost their sense of smell (hyposmia), no effective method exists to treat many of these people.

8 Apr 2008

London School of Hygiene and Tropical Medicine receives new Gates funding to fight disease

The London School of Hygiene & Tropical Medicine (LSHTM) has been awarded grant funding totalling $46.4 million from the Bill and Melinda Gates Foundation (BMGF) and $12.7 million from other partners, to help find new and effective ways of treating and preventing malaria, tuberculosis (TB) and HIV/AIDS.

10 Mar 2008

Vaginal probiotic product reduce recurrence rate of bacterial vaginosis

A newly published double blind, randomised, placebo controlled study(1) shows that EcoVag, a patented vaginal probiotic product from the Danish company, Bifodan, significantly reduces the recurrence rate of Bacterial Vaginosis (BV) following antibiotic treatment.

31 Jan 2008

Why we sleep - roundworm C. elegans unlocks sleep mysteries

The roundworm C. elegans, a staple of laboratory research, may be key in unlocking one of the central biological mysteries: why we sleep.

15 Jan 2008

New analyses of long-term LIALDA (mesalamine) data presented at ACG

Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.

16 Oct 2007

Aida granted new anti-cancer patent

One of mainland China's leading pharmaceutical companies, has announced that it was granted an additional patent related to its Rh-Apo2L anti-cancer drug, the second of three patents that had been applied for which Aida believes places it at the vanguard of China's pharmaceutical industry.

12 Oct 2007